Dettagli del progetto

Costo totale:

Contributo UE:

Coordinato in:

Argomento (i):

Meccanismo di finanziamento:

CSC - Cost-sharing contracts

Obiettivo

Allogeneic stem cell transplantation (SCT) is the only means of cure for haematological malignancies, as well as congenital anaemias and immunodeficiency disorders. The current poor rate of survival (30-50%) is due to post transplant complications, including infectious episodes, relapse (a lack of a graft versus leukaemia (GvL) effect) and graft versus host disease (GvHD). Tools to predict acute and chronic GvHD and/or GvL following different types of allogeneic SCT would enable new clinical protocols and therapeutics strategies to be developed based on individual patient expected risk. By the use of in vitro biotechnology, genetic and clinical risk assessments, we aim to predict outcome following therapy and SCT; develop new Europe-wide common clinical protocols and improve current therapeutic strategies.